Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 6/2018

Ausgabe 6/2018

Inhaltsverzeichnis ( 21 Artikel )

06.03.2018 | PRECLINICAL STUDIES | Ausgabe 6/2018

Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells

Songlin Liu, Yunhong Tang, Xianrui Yuan, Dun Yuan, Junyu Liu, Buyan Li, Yifeng Li

17.03.2018 | PRECLINICAL STUDIES | Ausgabe 6/2018 Open Access

The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivatives in human gastric cancer cells

Natalia Pawłowska, Agnieszka Gornowicz, Anna Bielawska, Arkadiusz Surażyński, Anna Szymanowska, Robert Czarnomysy, Krzysztof Bielawski

02.04.2018 | PRECLINICAL STUDIES | Ausgabe 6/2018

New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations

Elisabetta Bigagli, Cristina Luceri, Maria De Angioletti, Konstantin Chegaev, Mario D’Ambrosio, Chiara Riganti, Elena Gazzano, Simona Saponara, Mariangela Longini, Francesca Luceri, Lorenzo Cinci

28.03.2018 | PRECLINICAL STUDIES | Ausgabe 6/2018

Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation

Atsushi Osoegawa, Takafumi Hashimoto, Yohei Takumi, Miyuki Abe, Tomonori Yamada, Ryoji Kobayashi, Michiyo Miyawaki, Hideya Takeuchi, Tatsuro Okamoto, Kenji Sugio

05.05.2018 | PRECLINICAL STUDIES | Ausgabe 6/2018 Open Access

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker, Kees Bol, Mark Throsby, Cecile Geuijen, David Maussang, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema

03.04.2018 | PHASE I STUDIES | Ausgabe 6/2018

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris III, Lillian L. Siu, Lee-Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi Santiago-Walker, Jennifer L. Gauvin, Joyce M. Antal, Joanna B. Opalinska, Shannon R. Morris, Jeffrey R. Infante

10.04.2018 | PHASE I STUDIES | Ausgabe 6/2018

A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours

Kyaw L. Aung, Anthony B. El-Khoueiry, Karen Gelmon, Ben Tran, Gaurav Bajaj, Bing He, Tian Chen, Lili Zhu, Sharath Poojary, Shashwati Basak, Zhenhao Qi, Anna Spreafico, Bruce S. Fischer, Jayesh Desai

22.05.2018 | PHASE I STUDIES | Ausgabe 6/2018

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer

R. S. Finn, D. H. Ahn, M. M. Javle, B. R. Tan Jr, C. D. Weekes, J. C. Bendell, A. Patnaik, G. N. Khan, D. Laheru, R. Chavira, J. Christy-Bittel, E. Barrett, M. B. Sawyer, Tanios S. Bekaii-Saab

29.05.2018 | PHASE I STUDIES | Ausgabe 6/2018

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors

Sandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, Jaafar Bennouna, Mouna Sassi, Hélène de Mont-Serrat, Jean Fan, David Schnell, Jean-Pierre Delord

07.07.2018 | PHASE I STUDIES | Ausgabe 6/2018

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

Michael Carducci, Montaser Shaheen, Ben Markman, Sara Hurvitz, Daruka Mahadevan, Dusan Kotasek, Oscar B. Goodman Jr, Erik Rasmussen, Vincent Chow, Gloria Juan, Gregory R. Friberg, Erick Gamelin, Florian D. Vogl, Jayesh Desai

10.09.2018 | PHASE II STUDIES | Ausgabe 6/2018

Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients

Won Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, Do-Young Kim, Takuji Okusaka, Masafumi Ikeda, Hisashi Hidaka, Jong-Eun Yeon, Eishiro Mizukoshi, Manabu Morimoto, Myung-Ah Lee, Kohichiroh Yasui, Yasunori Kawaguchi, Jeong Heo, Sojiro Morita, Tae-You Kim, Junji Furuse, Kazuhiro Katayama, Takeshi Aramaki, Rina Hara, Takuya Kimura, Osamu Nakamura, Masatoshi Kudo

06.09.2018 | PHASE II STUDIES | Ausgabe 6/2018

Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study

Pedro C. Barata, Matthew Cooney, Prateek Mendiratta, Allison Tyler, Robert Dreicer, Jorge A. Garcia

15.10.2018 | PHASE II STUDIES | Ausgabe 6/2018

Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases

Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Kei Saito, Hiroki Oyama, Sachiko Kanai, Tatsunori Suzuki, Tatsuya Sato, Ryunosuke Hakuta, Kazunaga Ishigaki, Tsuyoshi Takeda, Tomotaka Saito, Suguru Mizuno, Hirofumi Kogure, Minoru Tada, Kazuhiko Koike

11.10.2018 | PHASE II STUDIES | Ausgabe 6/2018

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β

Clinton Yam, Rashmi K. Murthy, Gaiane M. Rauch, James L. Murray, Ronald S. Walters, Vicente Valero, Abenaa M. Brewster, Robert C. Bast Jr, Daniel J. Booser, Sharon H. Giordano, Francisco J. Esteva, Wei Yang, Gabriel N. Hortobagyi, Stacy L. Moulder, Banu Arun

22.10.2018 | PHASE II STUDIES | Ausgabe 6/2018

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone

Giandomenico Roviello, Roberto Petrioli, Alberto Bonetta, Raffaele Conca, Maria Grazia Rodriquenz, Michele Aieta

06.08.2018 | REVIEW | Ausgabe 6/2018

Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma

Chongchong Wang, Juehua Jing, Li Cheng

07.08.2018 | REVIEW | Ausgabe 6/2018

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

Navid Sobhani, Daniele Generali, Alberto D’Angelo, Michele Aieta, Giandomenico Roviello

26.06.2018 | SHORT REPORT | Ausgabe 6/2018

Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction

Kei Kunimasa, Taiki Isei, Harumi Nakamura, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Toru Kumagai, Shin-ichi Nakatsuka, Hiroko Endo, Masahiro Inoue, Fumio Imamura

28.06.2018 | SHORT REPORT | Ausgabe 6/2018

Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints

Sarah E. Stump, Young E. Whang, Daniel J. Crona

18.07.2018 | SHORT REPORT | Ausgabe 6/2018

Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors

Shewei Guo, Yingwei Zhen, Mengguo Guo, Longzhou Zhang, Guosheng Zhou

18.10.2018 | Correction | Ausgabe 6/2018

Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer

Laura W. Goff, Nilofer S. Azad, Stacey Stein, Jennifer G. Whisenant, Tatsuki Koyama, Ulka Vaishampayan, Howard Hochster, Roisin Connolly, Amy Weise, Patricia M. LoRusso, Safia N. Salaria, Wael El-Rifai, Jordan D. Berlin

Aktuelle Ausgaben


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise